Apr 23, 2020   SOURCE: PR NewsWire

FDA Warns Companies Illegally Selling CBD Products to Treat Medical Conditions, Opioid Addiction

SILVER SPRING, Md., April 23, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration has issued warning letters to two companies for illegally selling unapproved products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug and Cosmetic Act (FD&C Act). This action is a continuation of the FDA's efforts to pursue companies that illegally market CBD products with claims that they can treat medical conditions, including opioid addiction or as an alternative to opioids.

"The opioid crisis continues to be a serious problem in the United States, and we will continue to crack down on companies that attempt to benefit from selling products with unfounded treatment claims," said FDA Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D. "CBD has not been shown to treat opioid addiction. Opioid addiction is a real problem in our country, and those who are addicted need to seek out proper treatment from a health care provider. There are many unanswered questions about the science, safety, effectiveness and quality of unapproved products containing CBD, and we will continue to work to protect the health and safety of American consumers from products that are being marketed in violation of the law."

The two warning letters were issued to:

    --  BIOTA Biosciences, LLC of Washington state for marketing and
        distributing injectable CBD products as well as an injectable curcumin
        product. These products are marketed for serious diseases and as an
        alternative to opioids. BIOTA Biosciences markets private label CBD and
        wholesale CBD extracts, and their products include beverages, bulk CBD
        extracts, and water soluble CBD, as well as injectable curcumin.
    --  Homero Corp DBA Natures CBD Oil Distribution of New Hampshire for
        marketing and distributing CBD products as a treatment to opioid
        addiction as well as other serious diseases. The firm is an own label
        distributor for CBD products as well as a retailer for Green Roads CBD
        products.

Under the FD&C Act, any product intended to treat a disease or otherwise have a therapeutic or medical use, and any product (other than a food) that is intended to affect the structure or function of the body of humans or animals, is a drug. The FDA has not approved any CBD products other than one prescription human drug product to treat rare, severe forms of epilepsy.

Unlike drugs approved by the FDA, there has been no FDA evaluation of whether these unapproved products are effective for their intended use, what the proper dosage might be, how they could interact with FDA-approved drugs, or whether they have dangerous side effects or other safety concerns. In addition, the manufacturing process of unapproved CBD drug products has not been subject to FDA review as part of the human or animal drug approval processes. Consumers may also put off getting important medical care, such as proper diagnosis, treatment and supportive care due to unsubstantiated claims associated with CBD products. For that reason, it's important that consumers talk to a health care professional about the best way to treat diseases or conditions with existing, approved treatment options.

In March, the FDA provided updates on its work related to CBD products with a focus on protecting public health and providing market clarity. The FDA continues to be concerned that some people wrongly think that the myriad of CBD products on the market have been evaluated by the FDA and determined to be safe, or that using CBD "can't hurt." The FDA remains focused on educating the public about the number of questions that remain regarding CBD's safety. There may be risks that need to be considered before using CBD products outside of the monitored setting of a prescription from your health care provider.

The FDA has requested responses from the companies within 15 working days stating how they will correct the violations. Failure to correct the violations promptly may result in legal action, including product seizure and/or injunction.

Additional Resources:

    --  FDA Warning Letters
    --  What You Need to Know (And What We're Working to Find Out) About
        Products Containing Cannabis or Cannabis-derived Compounds, Including
        Cannabidiol (CBD)
    --  FDA is Committed to Sound, Science-based Policy on CBD
    --  FDA Regulation of Cannabis and Cannabis-Derived Products, Including
        Cannabidiol (CBD)

Media Contact: Nathan Arnold, (301) 796-6248
Consumer Inquiries: 888-INFO-FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

View original content to download multimedia:http://www.prnewswire.com/news-releases/fda-warns-companies-illegally-selling-cbd-products-to-treat-medical-conditions-opioid-addiction-301046314.html

SOURCE U.S. Food and Drug Administration